Skip to main navigation Skip to search Skip to main content

Comparability of anti-Xa assessments using alternate calibration curves in patients receiving rivaroxaban and apixaban therapy.

  • Leitinger, Emma Jane (Primary Chief Investigator (PCI))
  • Chunilal, Sanjeev (Chief Investigator (CI))

Project: Research

Project Details

Short titleClexane AXa calibrator for the DOACs ApixaBan and RivAroxaban
AcronymCADABRA
StatusFinished
Effective start/end date1/07/22 → 1/07/23

Funding

  • CSL Behring (United States of America): A$37,679.31
  • CSL Behring (United States of America): A$2,110.04